Minimal Macroscopic Residual Disease (0.1-1 cm). Is It Still a Surgical Goal in Advanced Ovarian Cancer?

International Journal of Gynecological Cancer

Volumn 26, Issue 5, 2016, Pages 906-911

  Chiva, Luis M ^a   Castellanos, Teresa ^a   Alonso, Sonsoles ^a   Gonzalez Martin, Antonio ^a  

^a MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Cytoreduction; Ovarian cancer; Residual disease; Surgery

Indexed keywords

CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; MEDLINE; MINIMAL RESIDUAL DISEASE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; AGED; CANCER STAGING; FEMALE; GYNECOLOGIC SURGERY; HUMAN; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; STANDARDS;

AGED; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84973400168     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000690     Document Type: Review

References (22)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
2. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26-31.
3. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-104.
4. Chang SJ, Hodeib M, Chang J, et al. Su rvival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-Analysis. Gynecol Oncol. 2013;130:493-498.
5. Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627.
6. Barlin JN, Long KC, Tanner EJ, et al. Optimal (e1 cm) but visible residual disease: is extensive debulking warranted? Gynecol Oncol. 2013;130:284-288.
7. Harter P, Muallem ZM, Buhrmann C, et al. Impact of a structured quality management program on surgical ou tcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121:615-619.
8. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;73:750-755.
9. Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical ou tcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and t he Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115():1234-1244.
10. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based t reatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
11. Colombo PE, Mourregot A, Fabbro M, et al. Aggressi ve surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol. 2009;35: 135-143.
12. Vergote I, TropéCG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
13. Peiretti M, Zanagnolo V, Aletti GD, et al. Role of maximal primary cytoreductive surgery i n patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010;119:259-264.
14. Chi DS, Musa F, Dao F, et al. An an alysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol O ncol. 2012;124:10-14.
15. Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19:4059-4067.
16. Hyman DM, Long KC, Tanner EJ, et al. Outcomes of primary surgical cytoreduction in patients with BRCA-Associated high-grade serous ovarian carcinoma. Gynecol Oncol. 2012;126:224-228.
17. Rauh-Hain JA, Nitschmann CC, Worley MJ Jr., et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013;129:63-68.
18. Landrum LM, Java J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2 013;130:12-18.
19. Rosen B,Laframboise S,Ferguson S,et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer Gynecol Oncol. 2014 134 462-467.
20. Fagö-Olsen CL, Ottesen B, Kehlet H, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecol Oncol. 2014;132 :292-298.
21. Fagotti A, Vizzielli G, Fanfani F, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single instit ution experience. Gynecol Oncol. 2013;131:341-346.
22. Chiva L, Lapuente F, Castellanos T, et al. What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer? Ann Surg Oncol. 2015 Dec 29. [Epub ahead of print].